Drugs / P2G12
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02923999 | Aug 2019 → Aug 2020 | HIV infectious disease | St George's, University of London | Unknown | No outcome recorded |
| Phase 1 | NCT01403792 | Jun → Nov 2011 | HIV infectious disease | University of Surrey | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | P2G12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02923999 ↗ |
| Action | Inhibit | “a monoclonal antibody which neutralises HIV-1 (P2G12)” NCT02923999 ↗ |
| Modality | Monoclonal antibody | “P2G12 is a monoclonal antibody (MAb) (a kind of protein)” NCT01403792 ↗ |
| Route | Intravenous | “Infusion will be administered intravenously using an infusion pump.” NCT02923999 ↗ |